These preliminary findings suggest that there may be some clinical benefits to IGFBP3 therapy in GIST patients, but further studies are needed to better characterize the functions of IGFBP3 in GIST. This evidence concerns the gene IGFBP3 and gastrointestinal stromal tumor.